Posted by Michael Wonder on 06 Sep 2023
MHRA approves Pfizer/BioNTech’s adapted COVID-19 vaccine (Comirnaty) that targets Omicron XBB.1.5
5 September 2023 - Approval has today been granted by the MHRA for an adapted Pfizer/BioNTech COVID-19 vaccine that targets the Omicron XBB 1.5 sub-variant, after it was found to meet the UK regulator’s standards of safety, quality and effectiveness.
The vaccine has been approved for use in individuals from 6 months of age.
